Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Leprosy drug clofazimine activates peroxisome proliferator-activated receptor-γ and synergizes with imatinib to inhibit chronic myeloid leukemia cells.

Kumar H, Chattopadhyay S, Das N, Shree S, Patel D, Mohapatra J, Gurjar A, Kushwaha S, Singh AK, Dubey S, Lata K, Kushwaha R, Mohammed R, Ghosh Dastidar K, Yadav N, Vishwakarma AL, Gayen JR, Bandyopadhyay S, Chatterjee A, Jain MR, Tripathi AK, Trivedi AK, Chattopadhyay N, Ramachandran R, Sanyal S.

Haematologica. 2019 Aug 1. pii: haematol.2018.194910. doi: 10.3324/haematol.2018.194910. [Epub ahead of print]

2.

Activation of GLP-1 and Glucagon Receptors Regulates Bile Homeostasis Independent of Thyroid Hormone.

Patel VJ, Joharapurkar AA, Kshirsagar SG, Sutariya BK, Patel MS, Bahekar RH, Jain MR.

Curr Mol Pharmacol. 2019;12(2):139-146. doi: 10.2174/1874467212666190212112402.

PMID:
30747091
3.

Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats.

Giri P, Delvadia P, Ladani MK, Prajapati N, Gupta L, Patel N, Joshi V, Giri S, Jain MR, Srinivas NR, Patel PR.

Eur J Pharm Sci. 2019 Mar 15;130:107-113. doi: 10.1016/j.ejps.2019.01.005. Epub 2019 Jan 8.

PMID:
30633968
4.

Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1.

Jain MR, Mohapatra J, Bandhyopadhyay D, Chatterjee A, Ghoshdastidar K, Patel D, Patel A, Bhayani H, Srivastava BK, Shedage SA, Kadam P, Sundar R, Patel H, Giri P, Patel P, Gupta L, Srinivas NR, Patel PR, Desai RC.

Cancer Chemother Pharmacol. 2018 Oct;82(4):635-647. doi: 10.1007/s00280-018-3653-1. Epub 2018 Jul 25.

PMID:
30046848
5.

Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus.

Patel VJ, Joharapurkar AA, Kshirsagar SG, Sutariya BK, Patel MS, Patel HM, Pandey DK, Bahekar RH, Jain MR.

World J Diabetes. 2018 Jun 15;9(6):80-91. doi: 10.4239/wjd.v9.i6.80.

6.

Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.

Joharapurkar AA, Pandya VB, Patel VJ, Desai RC, Jain MR.

J Med Chem. 2018 Aug 23;61(16):6964-6982. doi: 10.1021/acs.jmedchem.7b01686. Epub 2018 May 9. Review.

PMID:
29712435
7.

Preclinical evaluation of saroglitazar magnesium, a dual PPAR-α/γ agonist for treatment of dyslipidemia and metabolic disorders.

Patel H, Giri P, Patel P, Singh S, Gupta L, Patel U, Modi N, Shah K, Jain MR, Srinivas NR, Patel P.

Xenobiotica. 2018 Dec;48(12):1268-1277. doi: 10.1080/00498254.2017.1413264. Epub 2017 Dec 22.

PMID:
29224415
8.

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models.

Jain MR, Giri SR, Bhoi B, Trivedi C, Rath A, Rathod R, Ranvir R, Kadam S, Patel H, Swain P, Roy SS, Das N, Karmakar E, Wahli W, Patel PR.

Liver Int. 2018 Jun;38(6):1084-1094. doi: 10.1111/liv.13634. Epub 2017 Dec 14.

9.

Erratum. Pathophysiological Mechanism of Bone Loss in Type 2 Diabetes Involves Inverse Regulation of Osteoblast Function by PGC-1α and Skeletal Muscle Atrogenes: AdipoR1 as a Potential Target for Reversing Diabetes-Induced Osteopenia. Diabetes 2015;64:2609-2623.

Khan MP, Singh AK, Joharapurkar AA, Yadav M, Shree S, Kumar H, Gurjar A, Mishra JS, Tiwari MC, Nagar GK, Kumar S, Ramachandran R, Sharan A, Jain MR, Trivedi AK, Maurya R, Godbole MM, Gayen JR, Sanyal S, Chattopadhyay N.

Diabetes. 2017 Dec;66(12):3142-3143. doi: 10.2337/db17-er12b. Epub 2017 Oct 5. No abstract available.

10.

Balanced Coagonist of GLP-1 and Glucagon Receptors Corrects Dyslipidemia by Improving FGF21 Sensitivity in Hamster Model.

Patel V, Joharapurkar A, Kshirsagar S, Patel HM, Pandey D, Patel D, Sutariya B, Patel M, Bahekar R, Jain MR.

Drug Res (Stuttg). 2017 Dec;67(12):730-736. doi: 10.1055/s-0043-118808. Epub 2017 Sep 12.

11.

Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers.

Kansagra KA, Parmar D, Jani RH, Srinivas NR, Lickliter J, Patel HV, Parikh DP, Heading H, Patel HB, Gupta RJ, Shah CY, Patel MR, Dholakia VN, Sukhadiya R, Jain MR, Parmar KV, Barot K.

Clin Pharmacokinet. 2018 Jan;57(1):87-102. doi: 10.1007/s40262-017-0551-3.

12.

ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase-4, for the treatment of Type 2 diabetes mellitus.

Jain MR, Joharapurkar AA, Kshirsagar SG, Patel VJ, Bahekar RH, Patel HV, Jadav PA, Patel PR, Desai RC.

Br J Pharmacol. 2017 Jul;174(14):2346-2357. doi: 10.1111/bph.13842. Epub 2017 Jun 13.

13.

Central and Peripheral Glucagon Reduces Hyperlipidemia in Rats and Hamsters.

Patel V, Joharapurkar A, Kshirsagar S, Patel HM, Pandey D, Patel D, Shah K, Bahekar R, Shah GB, Jain MR.

Drug Res (Stuttg). 2017 Jun;67(6):318-326. doi: 10.1055/s-0043-102405. Epub 2017 Apr 26.

PMID:
28445900
14.

Is the Inhibition of Dipeptidyl Peptidase-4 (DDP-4) Enzyme Route Dependent and/or Driven by High Peak Concentration?- Seeking Answers with ZYDPLA1, a Novel Long Acting DPP-4 Inhibitor, in a Rodent Model.

Patel H, Joharapurkar AA, Bahekar R, Patel P, Kshirsagar SG, Modi N, Ghoghari A, Patel VJ, Jain MR, Srinivas NR, Patel PR, Desai RC.

Drug Res (Stuttg). 2017 Apr;67(4):223-227. doi: 10.1055/s-0042-122776. Epub 2017 Feb 3.

PMID:
28158894
15.

Nectin-like 4 Complexes with Choline Transporter-like Protein-1 and Regulates Schwann Cell Choline Homeostasis and Lipid Biogenesis in Vitro.

Heffernan C, Jain MR, Liu T, Kim H, Barretto K, Li H, Maurel P.

J Biol Chem. 2017 Mar 17;292(11):4484-4498. doi: 10.1074/jbc.M116.747816. Epub 2017 Jan 24.

16.

Influence of acute and chronic kidney failure in rats on the disposition and pharmacokinetics of ZYAN1, a novel prolyl hydroxylase inhibitor, for the treatment of chronic kidney disease-induced anemia.

Patel H, Joharapurkar AA, Pandya VB, Patel VJ, Kshirsagar SG, Patel P, Gevriya B, Jain MR, Srinivas NR, Patel PR, Desai RC.

Xenobiotica. 2018 Jan;48(1):37-44. doi: 10.1080/00498254.2016.1278287. Epub 2017 Jan 19.

PMID:
28042744
17.

Effect of pioglitazone on metabolic features in endotoxemia model in obese diabetic db/db mice.

Sharma M, Mohapatra J, Malik U, Nagar J, Chatterjee A, Ramachandran B, Jain MR.

J Diabetes. 2017 Jun;9(6):613-621. doi: 10.1111/1753-0407.12450. Epub 2016 Aug 17.

PMID:
27530729
18.

Cardioprotective role of peroxisome proliferator-activated receptor-γ agonist, rosiglitazone in a unique murine model of diabetic cardiopathy.

Giri SR, Bhoi B, Jain MR, Gatne MM.

Life Sci. 2016 Oct 1;162:1-13. doi: 10.1016/j.lfs.2016.08.013. Epub 2016 Aug 13.

PMID:
27530514
19.

Role of radiological-assisted cytology in intra-abdominal lesions: A 3 years' experience in a tertiary care center.

Dosi S, Gupta G, Kawatra M, Chakrabarti PR, Agrawal P, Jain MR.

Int J Appl Basic Med Res. 2016 Apr-Jun;6(2):101-5. doi: 10.4103/2229-516X.179022.

20.

Identification of novel S-nitrosation sites in soluble guanylyl cyclase, the nitric oxide receptor.

Beuve A, Wu C, Cui C, Liu T, Jain MR, Huang C, Yan L, Kholodovych V, Li H.

J Proteomics. 2016 Apr 14;138:40-7. doi: 10.1016/j.jprot.2016.02.009. Epub 2016 Feb 18.

21.

Central GLP-1 receptor activation improves cholesterol metabolism partially independent of its effect on food intake.

Patel V, Joharapurkar AA, Kshirsagar SG, Patel KN, Bahekar R, Shah G, Jain MR.

Can J Physiol Pharmacol. 2016 Feb;94(2):161-167. doi: 10.1139/cjpp-2014-0457. Epub 2015 Jul 29.

PMID:
26629909
22.

MicroRNA-7 activates Nrf2 pathway by targeting Keap1 expression.

Kabaria S, Choi DC, Chaudhuri AD, Jain MR, Li H, Junn E.

Free Radic Biol Med. 2015 Dec;89:548-56. doi: 10.1016/j.freeradbiomed.2015.09.010. Epub 2015 Oct 8.

23.

Spontaneous lesions in endocrine glands of experimental Wistar rats and beagle dogs.

Nataraju GJ, Ranvir RK, Kothule VR, Kadam SB, Ravichandra BV, Bhatnagar U, Jain MR.

Exp Toxicol Pathol. 2016 Jan;68(1):1-13. doi: 10.1016/j.etp.2015.09.002. Epub 2015 Sep 26.

PMID:
26414849
24.

Master redox regulator Trx1 upregulates SMYD1 & modulates lysine methylation.

Liu T, Wu C, Jain MR, Nagarajan N, Yan L, Dai H, Cui C, Baykal A, Pan S, Ago T, Sadoshima J, Li H.

Biochim Biophys Acta. 2015 Dec;1854(12):1816-1822. doi: 10.1016/j.bbapap.2015.09.006. Epub 2015 Sep 26.

25.

Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia.

Jain MR, Joharapurkar AA, Pandya V, Patel V, Joshi J, Kshirsagar S, Patel K, Patel PR, Desai RC.

Drug Res (Stuttg). 2016 Feb;66(2):107-12. doi: 10.1055/s-0035-1554630. Epub 2015 Sep 14.

PMID:
26367279
26.

Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models.

Jain MR, Giri SR, Trivedi C, Bhoi B, Rath A, Vanage G, Vyas P, Ranvir R, Patel PR.

Pharmacol Res Perspect. 2015 Jun;3(3):e00136. doi: 10.1002/prp2.136. Epub 2015 May 4.

27.

Differential effects of dexamethasone and rosiglitazone in a sephadex-induced model of lung inflammation in rats: possible role of tissue inhibitor of metalloproteinase-3.

Nagar JK, Patel PP, Mohapatra JN, Sharma MM, Pandya GM, Umar MM, Chatterjee AA, Deshpande SS, Jain MR, Soni HM.

Indian J Pharmacol. 2015 Mar-Apr;47(2):153-9. doi: 10.4103/0253-7613.153421.

28.

Effects of combination of aliskiren and pentoxyfylline on renal function in the rat remnant kidney model of chronic renal failure.

Soni HM, Patel PP, Patel S, Rath AC, Acharya A, Trivedi HD, Jain MR.

Indian J Pharmacol. 2015 Jan-Feb;47(1):80-5. doi: 10.4103/0253-7613.150351.

29.

Pathophysiological Mechanism of Bone Loss in Type 2 Diabetes Involves Inverse Regulation of Osteoblast Function by PGC-1α and Skeletal Muscle Atrogenes: AdipoR1 as a Potential Target for Reversing Diabetes-Induced Osteopenia.

Khan MP, Singh AK, Joharapurkar AA, Yadav M, Shree S, Kumar H, Gurjar A, Mishra JS, Tiwari MC, Nagar GK, Kumar S, Ramachandran R, Sharan A, Jain MR, Trivedi AK, Maurya R, Godbole MM, Gayen JR, Sanyal S, Chattopadhyay N.

Diabetes. 2015 Jul;64(7):2609-23. doi: 10.2337/db14-1611. Epub 2015 Jan 29. Erratum in: Diabetes. 2017 Dec;66(12 ):3142-3143.

30.

Optimization of 1,2,5-thiadiazole carbamates as potent and selective ABHD6 inhibitors.

Patel JZ, Nevalainen TJ, Savinainen JR, Adams Y, Laitinen T, Runyon RS, Vaara M, Ahenkorah S, Kaczor AA, Navia-Paldanius D, Gynther M, Aaltonen N, Joharapurkar AA, Jain MR, Haka AS, Maxfield FR, Laitinen JT, Parkkari T.

ChemMedChem. 2015 Feb;10(2):253-65. doi: 10.1002/cmdc.201402453. Epub 2014 Dec 11.

31.

Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.

Patel KN, Joharapurkar AA, Patel V, Kshirsagar SG, Bahekar R, Srivastava BK, Jain MR.

Can J Physiol Pharmacol. 2014 Dec;92(12):975-83. doi: 10.1139/cjpp-2014-0310. Epub 2014 Sep 29.

PMID:
25361428
32.

Therapeutic potential of coagonists of glucagon and GLP-1.

Patel VJ, Joharapurkar AA, Kshirsagar SG, Patel KN, Shah GB, Jain MR.

Cardiovasc Hematol Agents Med Chem. 2014;12(2):126-33. Review.

PMID:
25330114
33.

Pharmacological characterization of ZYDPLA1, a novel long-acting dipeptidyl peptidase-4 inhibitor.

Jain MR, Joharapurkar AA, Bahekar RH, Patel H, Jadav P, Kshirsagar SG, Patel VJ, Patel KN, Ramanathan VK, Patel PR, Desai RC.

J Diabetes. 2015 Sep;7(5):708-17. doi: 10.1111/1753-0407.12233. Epub 2014 Dec 17.

PMID:
25327540
34.

MicroRNA-7 protects against 1-methyl-4-phenylpyridinium-induced cell death by targeting RelA.

Choi DC, Chae YJ, Kabaria S, Chaudhuri AD, Jain MR, Li H, Mouradian MM, Junn E.

J Neurosci. 2014 Sep 17;34(38):12725-37. doi: 10.1523/JNEUROSCI.0985-14.2014.

35.

Identification of novel nuclear targets of human thioredoxin 1.

Wu C, Jain MR, Li Q, Oka S, Li W, Kong AN, Nagarajan N, Sadoshima J, Simmons WJ, Li H.

Mol Cell Proteomics. 2014 Dec;13(12):3507-18. doi: 10.1074/mcp.M114.040931. Epub 2014 Sep 17.

36.

Effect of GLP-1 based therapies on diabetic dyslipidemia.

Patel VJ, Joharapurkar AA, Shah GB, Jain MR.

Curr Diabetes Rev. 2014;10(4):238-50. Review.

PMID:
24998439
37.

Use of Aspirin in normalization of recombinant human erythropoietin-mediated hyper-reactivity of platelets in rats.

Soni HM, Vekaria AM, Rath AC, Belemkar S, Jain MR.

Indian J Pharmacol. 2014 May-Jun;46(3):328-33. doi: 10.4103/0253-7613.132187.

38.

Chemopreventive effect of a novel, selective TACE inhibitor on DMBA- and TPA-induced skin carcinogenesis.

Sharma M, Mohapatra J, Argade A, Deshpande SS, Shah GB, Chatterjee A, Jain MR.

Immunopharmacol Immunotoxicol. 2014 Aug;36(4):282-9. doi: 10.3109/08923973.2014.931421. Epub 2014 Jun 20.

PMID:
24946851
39.

Ameliorative potential of aliskiren in experimental colitis in mice.

Patel RB, Prajapati KD, Sonara BM, Sharma MM, Patel HM, Pawar VD, Jain MR.

Eur J Pharmacol. 2014 Aug 15;737:70-6. doi: 10.1016/j.ejphar.2014.05.009. Epub 2014 May 21.

PMID:
24858618
40.

Orally active osteoanabolic agent GTDF binds to adiponectin receptors, with a preference for AdipoR1, induces adiponectin-associated signaling, and improves metabolic health in a rodent model of diabetes.

Singh AK, Joharapurkar AA, Khan MP, Mishra JS, Singh N, Yadav M, Hossain Z, Khan K, Kumar S, Dhanesha NA, Mishra DP, Maurya R, Sharma S, Jain MR, Trivedi AK, Godbole MM, Gayen JR, Chattopadhyay N, Sanyal S.

Diabetes. 2014 Oct;63(10):3530-44. doi: 10.2337/db13-1619. Epub 2014 May 21.

41.

Mst1 promotes cardiac myocyte apoptosis through phosphorylation and inhibition of Bcl-xL.

Del Re DP, Matsuda T, Zhai P, Maejima Y, Jain MR, Liu T, Li H, Hsu CP, Sadoshima J.

Mol Cell. 2014 May 22;54(4):639-50. doi: 10.1016/j.molcel.2014.04.007. Epub 2014 May 8.

42.

Host biomarkers of invasive pulmonary aspergillosis to monitor therapeutic response.

Krel M, Petraitis V, Petraitiene R, Jain MR, Zhao Y, Li H, Walsh TJ, Perlin DS.

Antimicrob Agents Chemother. 2014 Jun;58(6):3373-8. doi: 10.1128/AAC.02482-14. Epub 2014 Mar 31.

43.

Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity.

Joharapurkar AA, Dhanesha NA, Jain MR.

Diabetes Metab Syndr Obes. 2014 Feb 28;7:73-84. doi: 10.2147/DMSO.S56924. eCollection 2014. Review.

44.

Involvement of TACE in colon inflammation: a novel mechanism of regulation via SIRT-1 activation.

Sharma M, Mohapatra J, Wagh A, Patel HM, Pandey D, Kadam S, Argade A, Deshpande SS, Shah GB, Chatterjee A, Jain MR.

Cytokine. 2014 Mar;66(1):30-9. doi: 10.1016/j.cyto.2013.12.010. Epub 2014 Jan 4.

PMID:
24548422
45.

Interconnected network motifs control podocyte morphology and kidney function.

Azeloglu EU, Hardy SV, Eungdamrong NJ, Chen Y, Jayaraman G, Chuang PY, Fang W, Xiong H, Neves SR, Jain MR, Li H, Ma'ayan A, Gordon RE, He JC, Iyengar R.

Sci Signal. 2014 Feb 4;7(311):ra12. doi: 10.1126/scisignal.2004621.

46.

Thyroid hormone modulates food intake and glycemia via ghrelin secretion in Zucker fatty rats.

Patel K, Joharapurkar A, Dhanesha N, Patel V, Kshirsagar S, Raval P, Raval S, Jain MR.

Drug Res (Stuttg). 2014 Oct;64(10):523-9. doi: 10.1055/s-0033-1363222. Epub 2013 Dec 19.

PMID:
24357139
47.

Blocking eIF5A modification in cervical cancer cells alters the expression of cancer-related genes and suppresses cell proliferation.

Mémin E, Hoque M, Jain MR, Heller DS, Li H, Cracchiolo B, Hanauske-Abel HM, Pe'ery T, Mathews MB.

Cancer Res. 2014 Jan 15;74(2):552-62. doi: 10.1158/0008-5472.CAN-13-0474. Epub 2013 Nov 12.

48.

Identification of Bax-interacting proteins in oligodendrocyte progenitors during glutamate excitotoxicity and perinatal hypoxia-ischemia.

Simonishvili S, Jain MR, Li H, Levison SW, Wood TL.

ASN Neuro. 2013 Dec 23;5(5):e00131. doi: 10.1042/AN20130027.

49.
50.

Proteomic mechanisms of cardioprotection during mammalian hibernation in woodchucks, Marmota monax.

Li H, Liu T, Chen W, Jain MR, Vatner DE, Vatner SF, Kudej RK, Yan L.

J Proteome Res. 2013 Sep 6;12(9):4221-9. doi: 10.1021/pr400580f. Epub 2013 Aug 6.

Supplemental Content

Support Center